10jili google search
RICHMOND, Va. , Nov. 22, 2024 /PRNewswire/ -- Universal Corporation (NYSE:UVV) ("Universal" or the "Company"), a global business-to-business agriproducts company, today announced that, as expected, on November 19, 2024 , it received a notice (the "NYSE Notice") from the New York Stock Exchange (the "NYSE") that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 (the "Form 10-Q") with the U.S. Securities and Exchange Commission (the "SEC") prior to November 18, 2024 , the end of the extension period provided by Rule 12b -25 under the Securities Exchange Act of 1934, as amended. The NYSE Notice has no immediate effect on the listing of the Company's common stock on the NYSE. The NYSE Notice informed the Company that, under NYSE rules, the Company has six months from November 18, 2024 , to regain compliance with the NYSE listing standards by filing the Form 10-Q with the SEC. If the Company fails to file the Form 10-Q within the six-month period, the NYSE may grant, in its sole discretion, an extension of up to six additional months for the Company to regain compliance, depending on the specific circumstances. The NYSE Notice also noted that the NYSE may nevertheless, in its own discretion, commence delisting proceedings at any time during such period. As previously disclosed in the Company's Notification of Late Filing on Form 12b-25, filed on November 12, 2024 (the "Form 12b-25") with the SEC, the Company was unable to file the Form 10-Q on a timely basis due to an ongoing internal investigation. As a result of the additional time required to complete its internal investigation, the process of finalizing financial statements for the second quarter of fiscal year 2025 could not be completed on a timely basis. The Company is committed to completing a deliberate, thorough investigation while diligently working to fulfill all reporting obligations and currently expects to file the Form 10-Q within the six-month period granted by the NYSE Notice; however, there can be no assurance that the Form 10-Q will be filed within such period. About Universal Corporation Universal Corporation (NYSE: UVV) is a global agricultural company with over 100 years of experience supplying products and innovative solutions to meet our customers' evolving needs and precise specifications. Through our diverse network of farmers and partners across more than 30 countries on five continents, we are a trusted provider of high-quality, traceable products. We leverage our extensive supply chain expertise, global reach, integrated processing capabilities, and commitment to sustainability to provide a range of products and services designed to drive efficiency and deliver value to our customers. For more information, visit www.universalcorp.com . CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Among other things, these statements include statements regarding expectations about the Company's filing of its Form 10-Q for the quarter ended September 30, 2024 . These forward-looking statements are generally identified by the use of words such as we "expect," "believe," "anticipate," "could," "should," "may," "plan," "will," "predict," "estimate," and similar expressions or words of similar import. These forward-looking statements are based upon management's current knowledge and assumptions about future events and involve risks and uncertainties that could cause actual results, performance, or achievements to be materially different from any anticipated results, prospects, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the uncertainty of the ultimate findings of the ongoing internal investigation, as well as the timing of its completion and costs and expenses arising out of the ongoing internal investigation process and its results; the impact of the ongoing internal investigation on us, our management and operations, including financial impact as well as any litigation or regulatory action that may arise from the ongoing internal investigation; the impact of the internal investigation on our conclusions regarding the effectiveness of our internal control over financial reporting and our disclosure controls and procedures; our ability to regain compliance with NYSE listing requirements; success in pursuing strategic investments or acquisitions and integration of new businesses and the impact of these new businesses on future results; product purchased not meeting quality and quantity requirements; our reliance on a few large customers; our ability to maintain effective information technology systems and safeguard confidential information; anticipated levels of demand for and supply of our products and services; costs incurred in providing these products and services including increased transportation costs and delays attributed to global supply chain challenges; timing of shipments to customers; higher inflation rates; changes in market structure; government regulation and other stakeholder expectations; economic and political conditions in the countries in which we and our customers operate, including the ongoing impacts from international conflicts; product taxation; industry consolidation and evolution; changes in exchange rates and interest rates; impacts of regulation and litigation on its customers; industry-specific risks related to its plant-based ingredient businesses; exposure to certain regulatory and financial risks related to climate change; changes in estimates and assumptions underlying our critical accounting policies; the promulgation and adoption of new accounting standards, new government regulations and interpretation of existing standards and regulations; and general economic, political, market, and weather conditions. Actual results, therefore, could vary from those expected. Please also refer to such other factors as discussed in Part I, Item 1A. "Risk Factors" of Universal's Annual Report on Form 10-K for the fiscal year ended March 31, 2024 , and related disclosures in other filings which have been filed with the U.S. Securities and Exchange Commission and are available on the SEC's website at www.sec.gov . All risk factors and uncertainties described herein and therein should be considered in evaluating forward-looking statements, and all of the forward-looking statements are expressly qualified by the cautionary statements contained or referred to herein and therein. Universal cautions investors not to place undue reliance on any forward-looking statements as these statements speak only as of the date when made, and it undertakes no obligation to update any forward-looking statements made, except as required by law. View original content to download multimedia: https://www.prnewswire.com/news-releases/universal-corporation-receives-nyse-notice-regarding-filing-of-form-10-q-for-the-fiscal-quarter-ended-september-30-2024-302314579.html SOURCE Universal Corporation
SAN DIEGO , Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the Company's headquarters from San Diego, California to Cary, North Carolina , effective January 1, 2025 . A majority of Heron's Management Team and corporate employees work from the Cary office, which is near the Research Triangle Park ("RTP"), one of the most prominent high-tech research and development parks in the United States . The growing biotech community in Cary and its surrounding areas provides ample space for growth and expansion. "We are excited to move our headquarters to Cary, North Carolina , which represents a significant milestone in Heron's journey," said Craig Collard , Chief Executive Officer of Heron. "This move will not only strengthen our ability to support our employees by centralizing our operations and resources, but also positions us in an excellent location from which we can continue making strategic partnerships as we growing our existing portfolio focused on improving the lives of patients in the acute and oncology care settings. This is an exciting chapter for Heron, and we look forward to the continued success and partnerships that lie ahead." The new address for Heron's corporate headquarters is 100 Regency Forest Drive, Suite 300, Cary, NC 27518. About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com . Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. iduarte@herontx.com 858-251-4400 View original content to download multimedia: https://www.prnewswire.com/news-releases/heron-therapeutics-announces-corporate-headquarters-relocation-to-cary-north-carolina-302338528.html SOURCE Heron Therapeutics, Inc.Palantir Technologies Inc. PLTR , whose shares have surged over 376% year-to-date, was better understood by retail investors than institutional ones during its challenging period in 2022 , according to Wedbush Securities Managing Director Dan Ives . What Happened : “Institutional investors were stuck in group-think when it came to Palantir as an investment in 2022. It wasn’t part of the cool kids club,” Ives said in an interview with Palantir investor Amit Kukreja . “People didn’t understand the culture of Palantir. We’re talking about the elite of the elite.” The data analytics company’s stock performance has made it the S&P 500’s top performer this year, pushing its market capitalization to $176.47 billion. However, this surge has raised valuation concerns among analysts, with the stock trading at 172 times its projected 2025 earnings – nearly triple the industry average of 59.4. See Also: Veteran Investor Bets Big On S&P 500 Hitting 7,000 By End Of 2025: These Sectors Could Lead The Charge Why It Matters : Despite the lofty valuation, Ives maintains his bullish stance with a $75 price target, describing Palantir as “the Messi of AI” and predicting significant AI spending growth in 2025 . UBS recently set a higher $80 target while maintaining a neutral rating, though expressing concerns about the current valuation at 49 times revenue. Former Palantir employee Alex Fishman , now with Empros Capital , reinforced the optimistic outlook : “When I look at Palantir, it’s one of the few companies where I can easily envision it becoming 10 or 20 times its current size.” The broader Wall Street consensus remains cautious, with an average price target of $35.58 based on 20 analyst ratings, suggesting potential downside risk despite the company’s strong momentum in artificial intelligence and data analytics. Price Action : Palantir stock closed at $79.08 on Friday, down 3.73% for the day, with after-hours trading seeing a further decline of 0.35%. Year to date, the stock has surged 376.96%. It has a 52-week range of $15.66 to $84.80 and a market capitalization of $176.47 billion. The stock’s price-to-earnings ratio stands at 410.70, with a 14-day Relative Strength Index of 56, suggesting neutral momentum, according to data from Benzinga Pro . Read Next: Boeing In Spotlight After Fatal 737-800 Crash In South Korea, Stock Declined 28% Amid Deepening 2024 Challenges Image Via Shutterstock Disclaimer : This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Valee and Surf Gang have teamed up for a new single, “Why Not,” ahead of their upcoming collaborative project, Grey Sky London , which will be dropping later this month. Evilgiane and NikeTech handled the production of the new single. Fans in the YouTube comments appear to be loving the track. “Best beat ive heard in a long ahhh time,” one user wrote. Another added: “I pretty much only listen to surf gang now.” In addition to “Why Not,” Grey Sky London will feature a total of five songs. They also include “Up Here,” “Hi Hater Maino ,” “Elbow,” and “By da Way.” The project marks one of numerous collaborations Surf Gang has put together as of late, following Jack & the Beanstalk with Lucy, Hard Copy with Bbyafricka, and Church & Surf with Durkalini. Evilgiane also recently dropped his own collaborative efforts, Evilslime , with Slimesito as well as .Bloody-Geeker* with Harto Falión. Just last week, he worked with Rojuu on the single, " Family Mart ." Check out Valee and Surf Gang’s “Why Not” below and be on the lookout for Grey Sky London on December 13th. In other music news , this month has already boasted releases from ghais guevara, Kodak Black , MIKE, Juice WRLD , and several more artists. Read More: ChaseTheMoney Is Working With Everyone: Offset, Lil Yachty, Valee & More Quotable Lyrics: It's gonna be hard as hell to bench me I'm taking the backstreet This ain't MLB I'm in Malibu b*tch gotta catch me Read More: evilgiane, sniper2004 & SADPONY Eschew The Hip-Hop Game On New Single "i don't wanna be a rapper": Stream
None